It will be several months before the first patient is dosed. It will be another few months to determine what the response was. Then you have to determine whether that response was greater than in patients who received just the chemo drug alone.  That is not a quick process.  Unless there is overwhelming evidence the drug peptide combination is far superior to anything else out there we're not gonna see any concrete data until the full analysis is done.  

I believe it will be effective. The big questions will be if it's more effective then just administering the chemo drug on its own. As well as toxicity from over accumulation in healthy tissues like the liver that also expressed sortilin.

 

SPCEO1 wrote:No oncology data until next year???? I am not sure why you think that. The trial is to start in the second quarter and since it is open label, we can expect to hear about any good news close to when the company discovers it. So, there shoould be quite a lot of important, likely market moving, cancer news this year. Moreover